MOTS-c is a 16 amino acid mitochondrial derived peptide encoded within the 12S ribosomal RNA region of the MTRNR1 gene. It is translated in the cytoplasm, highly conserved across species, and sits alongside humanin and the short humanin-like peptides in the mitochondrial derived peptide family. Its primary target is skeletal muscle, the site of most insulin-stimulated glucose disposal, which positions it as a signaling molecule worth understanding when evaluating metabolic and age-related decline.

This lesson covers mechanism, the current evidence base, and clinical context. MOTS-c is not FDA approved. It is a WADA-prohibited substance under the S2 peptide and hormone section, and since September 2023 it has been listed as an FDA category two bulk substance, which restricts compounding for human use. That classification is under reevaluation alongside roughly nineteen other peptides.

How it works

MOTS-c inhibits the folate cycle, driving accumulation of AICAR, which is a potent activator of AMPK. Downstream, AMPK activation supports glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and modulation rather than outright suppression of mTOR. Folate cycle inhibition can raise homocysteine modestly, which the speaker frames as a feature of the mechanism rather than a concern.

Under metabolic stress, glucose restriction, or oxidative stress, MOTS-c translocates from the mitochondria to the nucleus through AMPK. There it interacts with NRF2 and binds antioxidant response elements, enhancing transcription of genes such as heme oxygenase-1 and NQO1. Nuclear accumulation peaks around three hours post-stress and returns to baseline within 24 hours. This represents an example of mitonuclear communication, where the mitochondria signal cellular energy status back to the nucleus.

Evidence and clinical context

Preclinical data is strong for insulin sensitization, anti-obesity and thermogenic effects, anti-inflammatory activity, and exercise enhancement. Endogenous MOTS-c rose eleven to twelve fold in skeletal muscle after exercise, and systemic treatment improved treadmill performance and late-life physical capacity in aged mice. Human evidence is limited to observational exercise studies and phase one safety data on the CB4211 analog. Effects appear concentrated in metabolically challenged states, with limited benefit in healthy controls, and animal studies show metabolic benefits in males but not premenopausal females.

Reported clinical use is subcutaneous, commonly 5 to 10 mg starting at 5 mg, three times weekly, in cycles of roughly six to twelve weeks with time off afterward. No post-cycle therapy is needed, since endogenous production resumes on its own.

Key clinical points

• MOTS-c works through folate cycle inhibition, AICAR accumulation, AMPK activation, and NRF2-driven antioxidant gene expression.
• It is not FDA approved, is WADA-prohibited, and is a category two bulk substance with restricted compounding as of September 2023.
• Benefits appear specific to metabolically challenged states, with limited effect in healthy controls and observed sex differences in animal models.
• Use caution alongside metformin, aspirin, and other AMPK activators given hypoglycemia risk; avoid in cancer, pregnancy, and lactation.
• Suggested monitoring includes fasting glucose and insulin, A1C, HOMA-IR, metabolic and lipid panels, CRP, and body composition by DEXA or InBody.